Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

.

Other Chaperone Programs:

Amicus is accelerating its investment in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease, funded in part by a grant from the Michael J. Fox Foundation. In addition to the work in Parkinson's, Amicus is investing in new research aimed at evaluating disease targets for other neurodegenerative disorders and metabolic disorders.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire also reimburses worldwide development costs on a 50/50 basis. Under the agreement, Shire received rights to commercialize these products outside of the United States. Amicus retains all rights to commercialize these products in the United States. Amicus will lead development operations through the end of Phase 2 clinical trials. The companies will then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-US regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended March 31, 2008, was $7.7 million as compared to $9.7 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended March 31, 2008, was $6.4 million as compared to $8.9 million and the same period in 2007.

Amic
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Two new educational webinars hosted by ... ALS research and how the pharmaceutical industry can make life ... Challenge: Where Does the ALS Money Go? , Featuring guest ... Time: 1:30pm ET, Register to attend , This ... Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General Hospital ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed 137 ... Summit in San Francisco to take first place in ... Valley investors and technology elites as the premier showcase ... Briteseed to move on to the final phase ... with other elite innovation finalists for a $125,000 cash ...
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
(Date:11/21/2014)... November 20, 2014 The ... policy research organization representing leading California academic institutions, ... PwC US today released a report ... sciences industry growth. The trend shows a 4 ... 2015 California Biomedical Industry Report indicates that, ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... mortality faced by patients at ... national average, EL SEGUNDO, Calif., July 7 ... those diagnosed with chronic,kidney failure and disease (CKD), significantly ... by both the Clinical,Performance Measures Report published in 2006 ...
... Takes Over From Bernard Barataud, EVRY, France, July ... new president to head the laboratory created in 1990 ... succeeds Bernard,Barataud, who has decided to hand over the ... then between 1999 and 2008., Yves Champey is ...
... July 3 Bioheart, Inc.,(Nasdaq: BHRT ) ... development,of autologous (patient-derived) cell therapies and devices for ... announced that its Board,of Directors appointed Howard J. ... Technology Officer, to serve as Chief Executive,Officer effective ...
Cached Biology Technology:Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 2Superior Patient Clinical Outcomes Confirms DaVita's Leadership Position on Quality Dialysis Care 3A New President at the Head of the Genethon Laboratory 2Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer 2Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer 3
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3
... To promote the health of at-risk teenagers in Newark and ... The Horizon Foundation for New Jersey. ... to teach middle and high school students about nutrition, physical ... carried out by the Consortium for Pre-College Education in Greater ...
... of Anatomists has chosen Springer to publish its official ... issue will be published at Springer in April 2009. ... Anatomical Science International focuses on the morphological ... cellular, histological and gross anatomical studies. In addition ...
... world, nitrogen compounds are released to the atmosphere ... These pollutants are deposited to ecosystems as precipitation, ... downwind of their release point. The Catskill Mountains ... pointthough they contain little in the way of ...
Cached Biology News:Anatomical Science International joins Springer's publishing program 2Tree species composition influences nitrogen loss from forests 2
Request Info...
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... is an essential component of the COP9 ... various cellular and developmental processes. The CSN ... ubiquitin (Ubl) conjugation pathway by mediating the ... E3 ligase complexes. The complex is also ...
Biology Products: